Reviews
Clinical Proteomics: Revolutionizing Disease Detection and Patient Tailoring Therapy
To whom correspondence should be addressed. Dr. Emanuel F. Petricoin, CBER/FDA, Bldg. 29A/2D12, 8800 Rockville Pike, Bethesda, MD 20892. Tel: (301) 827-1753. Fax: (301) 480-5005. E-mail: petricoin@cber.fda.gov. Lance A. Liotta, CCR/NCI/NIH, 10 Center Drive, Bethesda, MD 20892. Tel: (301) 496-2035. E-mail: liottal@mail.nih.gov.
NCI/FDA Clinical Proteomics Program, Office of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration.
NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute.
Abstract

The evolving discipline of Clinical Proteomics is more than simply describing and enumerating the systematic changes in the protein constituency of a cell, or just generating lists of proteins that increase or decrease in expression as a cause or consequence of disease. Clinical applications of proteomics involve the use of proteomic technologies at the bedside with the ultimate goal to characterize the information flow through the intra- and extracellular molecular protein networks that interconnect organ and circulatory systems together. These networks are both new targets for therapeutics themselves as well as underpin the dynamic changes that give rise to cascades of new diagnostic biomarkers. The analysis of human cancer can be used as a model for how clinical proteomics is having an impact at the bedside for early detection, rational therapeutic targeting, and patient-tailored therapy.
Keywords: proteomics • pharmacoproteomics • patterns • mass spectrometry • protein microarrays
View: Full Text HTML | Hi-Res PDF
Tools
-
Add to Favorites
-
Download Citation
-
Email a Colleague -
Permalink
Order Reprints
Rights & Permissions
Citation Alerts
History
- Published In Issue April 12, 2004
- Received January 14, 2004
Cart


